News | November 04, 2025
Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VASOSTRICT Injection 40 Units per 100 mL and 20 Units per 100 mL of PH Health Limited
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA
Cenexi reports an EBITDA breakeven for the quarter
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The company expects to launch this product through its marketing partner in the near future
Subscribe To Our Newsletter & Stay Updated
